Myriad Genetics (MYGN)

• Market cap: $814M
• 1 day: -3.36%
• 5 days: -11.96%
• 1 month: -16.96%
• 3 months: -34.63%
• 6 months: -67.47%
• Year to date: -34.00%
• 1 year: -58.21%
• 5 years: -38.59%
• 10 years: -74.80%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Employees: 2,700

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,343% more call options, than puts

Call options by funds: $4.1M | Put options by funds: $284K

25% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 73

0.96% more ownership

Funds ownership: 100.51% [Q3] → 101.47% (+0.96%) [Q4]

11% less funds holding

Funds holding: 246 [Q3] → 218 (-28) [Q4]

45% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 56

49% less capital invested

Capital invested by funds: $2.5B [Q3] → $1.27B (-$1.23B) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $11 23% upside
• Avg. target: $17.44 96% upside
• High target: $29 225% upside

8 analyst ratings

• positive: 4 50%
• neutral: 3 38%
• negative: 1 13%

Piper Sandler Dave Weiner 0 / 0 met price target	40% upside $12.50	Overweight Upgraded	12 Mar 2025
B of A Securities Derik De Bruin 40% 1-year accuracy 8 / 20 met price target	23% upside $11	Underperform Maintained	3 Mar 2025
Raymond James Andrew Cooper 13% 1-year accuracy 2 / 15 met price target	113% upside $19	Outperform Reiterated	25 Feb 2025
UBS Lu Li 0% 1-year accuracy 0 / 3 met price target	80% upside $16	Neutral Maintained	25 Feb 2025
Craig-Hallum John Wilkin 33% 1-year accuracy 1 / 3 met price target	225% upside $29	Buy Initiated	12 Feb 2025